Barclays
PTHS

Barclays’s Pelthos Therapeutics PTHS Stock Holding History

Barclays’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$565 Buy
+20
New +$513 ﹤0.01% 4991
2025
Q2 		– Sell
-5
Closed -$77 – 5599
2025
Q1 		$77 Buy
+5
New +$86 ﹤0.01% 5134

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Barclays's PTHS Position: Q2 2026 in Review

Barclays opened a new position in Pelthos Therapeutics (PTHS) in Q2 2026: 20 shares worth $565. The stake represents ﹤0.01% of the portfolio and ranks #4991 among its holdings. This is a return to the name: Barclays previously reported a position in PTHS as recently as Q1 2025.

Barclays first reported a position in PTHS in Q1 2025 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Barclays held 20 shares of Pelthos Therapeutics worth $565 as of Q2 2026.
  • Pelthos Therapeutics was a new Barclays position in Q2 2026.
  • Pelthos Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4991 holding.
  • Barclays first reported a position in Pelthos Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.